Clinical Trials Browser

Esophageal Squamous Cell Carcinoma, Biliary Tract Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors

NCT01311713 2024-01-30

Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors

Phase 1/2 Terminated

45 enrolled 16 charts

Tumor-Agnostic

Neoplasms

NCT06121557 2023-11-08

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1 Recruiting

24 enrolled

Breast

Breast Neoplasms

NCT04724031 2023-03-14

Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

Unknown

150 enrolled

Gynecologic

Ovarian Neoplasms

NCT03182673 2022-09-01

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Phase 1 Terminated

31 enrolled

Other solid neoplasm

Solid Tumor

NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

Phase 2 Unknown

52 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT04774627 2021-09-23

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

Completed

200 enrolled

Tumor-Agnostic

Neoplasms

NCT05044091 2021-09-14

HOPEI

Unknown

100 enrolled

Gynecologic

Kenny-Caffey syndrome, Type 1, Ovarian Neoplasms

NCT03951415 2021-04-01

DOMEC

Phase 2 Unknown

55 enrolled

Gynecologic

Uterine Neoplasms, Endometrial Neoplasms

NCT04326023 2021-03-11

Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)

Completed

178 enrolled

Tumor-Agnostic

Neoplasms

NCT03227016 2021-01-27

Study in Patients With SCLC of Veliparib in Combination With Topotecan

Phase 1 Unknown

30 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04582552 2021-01-20

ROMP

Unknown

60 enrolled

Gynecologic

Ovarian Neoplasms

NCT01033123 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Phase 2 Completed

41 enrolled

Gynecologic

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

NCT01033292 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Phase 2 Completed

43 enrolled

Gynecologic

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

NCT02396433 2015-08-25

Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers

Phase 1/2 Withdrawn

Breast

Breast Neoplasms